Cargando…

Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins

The p53 protein is a key player in a wide range of protein networks that allow the state of “good health” of the cell. Not surprisingly, mutations of the TP53 gene are one of the most common alterations associated to cancer cells. Mutated forms of p53 (mtp53) not only lose the ability to protect the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Tiziana, Iezzi, Simona, Fanciulli, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753824/
https://www.ncbi.nlm.nih.gov/pubmed/26913241
http://dx.doi.org/10.3389/fonc.2016.00034
_version_ 1782415921479942144
author Bruno, Tiziana
Iezzi, Simona
Fanciulli, Maurizio
author_facet Bruno, Tiziana
Iezzi, Simona
Fanciulli, Maurizio
author_sort Bruno, Tiziana
collection PubMed
description The p53 protein is a key player in a wide range of protein networks that allow the state of “good health” of the cell. Not surprisingly, mutations of the TP53 gene are one of the most common alterations associated to cancer cells. Mutated forms of p53 (mtp53) not only lose the ability to protect the integrity of the genetic heritage of the cell but also acquire pro-oncogenic functions, behaving like dangerous accelerators of transformation and tumor progression. In recent years, many studies focused on investigating possible strategies aiming to counteract this mutant p53 “gain of function” but the results have not always been satisfactory. Che-1/AATF is a nuclear protein that binds to RNA polymerase II and plays a role in multiple fundamental processes, including control of transcription, cell cycle regulation, DNA damage response, and apoptosis. Several studies showed Che-1/AATF as an important endogenous regulator of p53 expression and activity in a variety of biological processes. Notably, this same regulation was more recently observed also on mtp53. The depletion of Che-1/AATF strongly reduces the expression of mutant p53 in several tumors in vitro and in vivo, making the cells an easier target for chemotherapy treatments. In this mini review, we report an overview of Che-1/AATF functions and discuss a possible role of Che-1/AATF in cancer therapy, with particular regard to its action on p53/mtp53.
format Online
Article
Text
id pubmed-4753824
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-47538242016-02-24 Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins Bruno, Tiziana Iezzi, Simona Fanciulli, Maurizio Front Oncol Oncology The p53 protein is a key player in a wide range of protein networks that allow the state of “good health” of the cell. Not surprisingly, mutations of the TP53 gene are one of the most common alterations associated to cancer cells. Mutated forms of p53 (mtp53) not only lose the ability to protect the integrity of the genetic heritage of the cell but also acquire pro-oncogenic functions, behaving like dangerous accelerators of transformation and tumor progression. In recent years, many studies focused on investigating possible strategies aiming to counteract this mutant p53 “gain of function” but the results have not always been satisfactory. Che-1/AATF is a nuclear protein that binds to RNA polymerase II and plays a role in multiple fundamental processes, including control of transcription, cell cycle regulation, DNA damage response, and apoptosis. Several studies showed Che-1/AATF as an important endogenous regulator of p53 expression and activity in a variety of biological processes. Notably, this same regulation was more recently observed also on mtp53. The depletion of Che-1/AATF strongly reduces the expression of mutant p53 in several tumors in vitro and in vivo, making the cells an easier target for chemotherapy treatments. In this mini review, we report an overview of Che-1/AATF functions and discuss a possible role of Che-1/AATF in cancer therapy, with particular regard to its action on p53/mtp53. Frontiers Media S.A. 2016-02-15 /pmc/articles/PMC4753824/ /pubmed/26913241 http://dx.doi.org/10.3389/fonc.2016.00034 Text en Copyright © 2016 Bruno, Iezzi and Fanciulli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bruno, Tiziana
Iezzi, Simona
Fanciulli, Maurizio
Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title_full Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title_fullStr Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title_full_unstemmed Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title_short Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
title_sort che-1/aatf: a critical cofactor for both wild-type- and mutant-p53 proteins
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753824/
https://www.ncbi.nlm.nih.gov/pubmed/26913241
http://dx.doi.org/10.3389/fonc.2016.00034
work_keys_str_mv AT brunotiziana che1aatfacriticalcofactorforbothwildtypeandmutantp53proteins
AT iezzisimona che1aatfacriticalcofactorforbothwildtypeandmutantp53proteins
AT fanciullimaurizio che1aatfacriticalcofactorforbothwildtypeandmutantp53proteins